Cellectis Announces Two Poster Presentations On Novel TALEN Editing Process For Gene Correction And Gene Insertion In HSPCs At The ASGCT Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company, announced its participation in the ASGCT Annual Meeting with two poster presentations on novel TALEN editing processes for gene correction and insertion in HSPCs. The presentations will showcase advancements in non-viral DNA template delivery and a promoter-less intron editing strategy for lineage-specific transgene expression.
April 08, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis is set to present novel gene editing processes at the ASGCT Annual Meeting, highlighting advancements in gene therapy.
The announcement of Cellectis' participation in the ASGCT Annual Meeting with innovative gene editing presentations is likely to generate positive attention from the scientific community and investors. Showcasing advancements in gene therapy, particularly in HSPCs, positions Cellectis as a leader in the field. This could lead to increased investor confidence and potentially positive movement in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90